Stemline Therapeutics Inc. (STML) Drops 7.08% on January 27

Equities Staff  |

Stemline Therapeutics Inc. (STML) was one of the Russell 2000's biggest losers for Wednesday January 27 as the stock slid 7.08% to $4.99, a loss of $-0.38 per share. Starting at an opening price of $5.33 a share, the stock traded between $4.96 and $5.38 over the course of the trading day. Volume was 43,676 shares over 385 trades, against an average daily volume of 106,342 shares and a total float of 18 million.

The losses send Stemline Therapeutics Inc. down to a market cap of $89.81 million. In the last year, Stemline Therapeutics Inc. has traded between $17.40 and $4.39, and its 50-day SMA is currently $6.67 and 200-day SMA is $10.24.

Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.

Stemline Therapeutics Inc. is based out of New York, NY and has some 27 employees. Its CEO is Ivan Bergstein.

For a complete fundamental analysis analysis of Stemline Therapeutics Inc., check out’s Stock Valuation Analysis report for STML. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.